Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells

Cardiovascular Research

Volumn 91, Issue 4, 2011, Pages 577-586

  Mehta, Ashish ^a   Chung, Ying Ying ^a   Ng, Alvin ^a   Iskandar, Fahamy ^b   Atan, Shirhan ^a   Wei, Heming ^a   Dusting, Greg ^c   Sun, William ^d   Wong, Philip ^a   Shim, Winston ^a  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

^b Singapore Health Services   (Singapore)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Agency for Science   (Singapore)

Author keywords

Cardiomyocyte; Differentiation; Drug screening; Induced pluripotent stem cell

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; ION CHANNEL; ISOPRENALINE; TETRODOTOXIN; TRANSCRIPTION FACTOR; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CHRONOTROPISM; ELECTRIC POTENTIAL; EMBRYONIC STEM CELL; FIBROBLAST; GENE EXPRESSION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; INOTROPISM; MESODERM; MICROELECTRODE; MOUSE; NONHUMAN; ONTOGENY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SARCOMERE; TERATOMA;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MYOCYTES, CARDIAC; VERAPAMIL;

EID: 80052007523     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr132     Document Type: Article

References (45)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282: 1145-1147. (Pubitemid 28516247)
2. Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Brink S, Hassink R et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003;107:2733-2740. (Pubitemid 36667249)
3. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell- derived population. Nature 2008;453:524-528. (Pubitemid 351733312)
4. Huber TL. Dissecting hematopoietic differentiation using the embryonic stem cell differentiation model. Int J Dev Biol 2010;54:991-1002.
5. Flora SJ, Mehta A. Monoisoamyl dimercaptosuccinic acid abrogates arsenic-induced developmental toxicity in human embryonic stem cell-derived embryoid bodies: comparison with in vivo studies. Biochem Pharmacol 2009;78:1340-1349.
6. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007;25:1015-1024. (Pubitemid 47517637)
7. Shim W, Mehta A, Lim SY, Zhang G, Lim CH, Chua T et al. G-CSF for stem cell therapy in acute myocardial infarction: friend or foe? Cardiovasc Res 2011;89:20-30.
8. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131: 861-872. (Pubitemid 350138099)
9. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318:1917-1920.
10. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010; 363:1397-1409.
11. Zwi L, Caspi O, Arbel G, Huber I, Gepstein A, Park IH et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 2009;120:1513-1523.
12. Freund C, Davis RP, Gkatzis K, Ward-van Oostwaard D, Mummery CL. The first reported generation of human induced pluripotent stem cells (iPS cells) and iPS cellderived cardiomyocytes in the Netherlands. Neth Heart J 2010;18:51-54.
13. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324:797-801.
14. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-317. (Pubitemid 47080336)
15. Sun N, Longaker MT, Wu JC. Human iPS cell-based therapy: considerations before clinical applications. Cell Cycle 2010;9:880-885.
16. Yusa K, Rad R, Takeda J, Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 2009;6:363-369.
17. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, Li Z et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods 2010;7:197-199.
18. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-630.
19. Mehta A, Konala VB, Khanna A, Majumdar AS. Assessment of drug induced developmental toxicity using human embryonic stem cells. Cell Biol Int 2008;32:1412-1424.
20. Mehta A, Mathew S, Viswanathan C, Sen Majumdar A. Intrinsic properties and external factors determine the differentiation bias of human embryonic stem cell lines. Cell Biol Int 2010;34:1021-1031.
21. Graichen R, Xu X, Braam SR, Balakrishnan T, Norfiza S, Sieh S et al. Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentiation 2008;76:357-370. (Pubitemid 351522761)
22. Ritner C, Bernstein HS. Fate mapping of human embryonic stem cells by teratoma formation. J Vis Exp 2010;42. http://www.jove.com/index/Details.stp?ID= 2036, doi:10.3791/2036.
23. Kehat I, Gepstein A, Spira A, Itskovitz-Eldor J, Gepstein L. High-resolution electrophysiological assessment of human embryonic stem cell-derived cardiomyocytes: a novel in vitro model for the study of conduction. Circ Res 2002;91:659-661. (Pubitemid 35204947)
24. Zhu WZ, Santana LF, Laflamme MA. Local control of excitation-contraction coupling in human embryonic stem cell-derived cardiomyocytes. PLoS One 2009;4:e5407.
25. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009;104: e30-e41.
26. Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001;108:407-414. (Pubitemid 32730787)
27. Osafune K, Caron L, Borowiak M, Martinez RJ, Fitz-Gerald CS, Sato Y et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 2008;26:313-315. (Pubitemid 351355125)
28. Moore JC, Fu J, Chan YC, Lin D, Tran H, Tse HF et al. Distinct cardiogenic preferences of two human embryonic stem cell (hESC) lines are imprinted in their proteomes in the pluripotent state. Biochem Biophys Res Commun 2008;372:553-558.
29. Pekkanen-Mattila M, Kerkelä E, Tanskanen JM, Pietilä M, Pelto-Huikko M, Hyttinen J et al. Substantial variation in the cardiac differentiation of human embryonic stem cell lines derived and propagated under the same conditions-a comparison of multiple cell lines. Ann Med 2009;41:360-370.
30. Zeineddine D, Papadimou E, Chebli K, Gineste M, Liu J, Grey C et al. Oct-3/4 dose dependently regulates specification of embryonic stem cells toward a cardiac lineage and early heart development. Dev Cell 2006;11:535-546. (Pubitemid 44430895)
31. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 2008;132:661-680. (Pubitemid 351260059)
32. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000;24:372-376. (Pubitemid 30187435)
33. Tomescot A, Leschik J, Bellamy V, Dubois G, Messas E, Bruneval P et al. Differentiation in vivo of cardiac committed human embryonic stem cells in postmyocardial infarcted rats. Stem Cells 2007;25:2200-2205. (Pubitemid 47480478)
34. Braam SR, Passier R, Mummery CL. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. Trends Pharmacol Sci 2009;30: 536-545.
35. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715. (Pubitemid 39173511)
36. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350: 1013-1022. (Pubitemid 38269278)
37. Satin J, Kehat I, Caspi O, Huber I, Arbel G, Itzhaki I et al. Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. J Physiol 2004;559: 479-496. (Pubitemid 39263813)
38. Zeng J, Rudy Y. Early afterdepolarizations in cardiac myocytes: mechanism and rate dependence. Biophys J 1995;68:949-964.
39. Kuzmenkin A, Liang H, Xu G, Pfannkuche K, Eichhorn H, Fatima A et al. Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro. FASEB J 2009;23:4168-4180.
40. Tanaka T, Tohyama S, Murata M, Nomura F, Kaneko T, Chen H et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun 2009;385:497-502.
41. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471: 225-229.
42. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 2011;32:952-962.
43. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007;1:39-49. (Pubitemid 46865811)
44. Nishikawa S, Goldstein RA, Nierras CR. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol 2008;9:725-729.
45. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008;105: 5856-5861. (Pubitemid 351758462)